-
Over $600 million!
Time of Update: 2022-02-24
Author: Bai LuOn December 20, Lineage Cell Therapeutics announced that it has signed an exclusive global collaboration and license agreement with its subsidiary Cell Cure Neurosciences and Roche subsidiary Genentech to jointly develop and commercialize retinal pigment epithelium (RPE) cell therapies for the treatment of eye diseases, Including advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA) .
-
The regulatory authorities combined fists to control the chaos of medical beauty, and Ai Weilan’s strict management ensured the efficacy of Tongyan acupuncture
Time of Update: 2022-02-24
With the increase in the market popularity of Aiweilan Tongyan Acupuncture, it is believed that this product has the strength to become another new favorite in the field of medical beauty .
-
21 When is the best time to take Jinweita?
Time of Update: 2022-02-24
Pay attention to health, and timely match nutritional supplement products other than three meals to maintain the nutritional balance of the body and ensure health .
As a nutritional supplement, 21 Gold Vita does not have a specific consumption time.
-
ALS patient tweets through brain-computer interface for the first time
Time of Update: 2022-02-24
O'Keefe's technology for sending messages was developed by the brain-computer interface company Synchron, and the device is called the Stentrode brain-computer interface (SBCI): an intravascular brain implant .
-
Blood test breakthrough in 2022 could boost Alzheimer's and Parkinson's diagnosis
Time of Update: 2022-02-24
Measuring certain types of tau in blood samples may be a better indicator of disease progression than amyloid beta, says Quanterix, another test development company whose technology has been used in Biogen and Eli Lilly's clinical trials .
-
Open a new strategy for gene therapy!
Time of Update: 2022-02-24
In a variety of human cells, the researchers demonstrated the broad editing capabilities of lead editing, not only precisely modifying individual bases, but also inserting or deleting specific DNA segments at specific locations in the genome .
-
Where is the next step for targeted protein degradation?
Time of Update: 2022-02-24
▲MDM2 is an E3 ligase that regulates p53 levels (Image source: Kymera official website)KT-253, a protein degrader targeting MDM2 developed by the company, has shown better activity than MDM2 small molecule inhibitors in preclinical experiments, can stabilize the level of p53, and lead to the death of cancer cells .
-
The little secret of cancer cells has been found and can no longer escape the pursuit of anti-cancer therapy!
Time of Update: 2022-02-24
According to a new study in Nature, researchers from Children's Hospital of Philadelphia (CHOP) used this property to create a new peptide-centric CAR-T cell (Peptide Centric CAR-T) .
After multiple rounds of screening, a peptide molecule that can show the existence of neuroblastoma and is presented by MHC can be transformed into CAR-T .
-
Eating wolfberry by mistake can easily hurt the body. It is important to keep these points in mind
Time of Update: 2022-02-24
But do you know the following points should be paid attention to when eating wolfberry?First of all, many dried goji berries on the market are smoked with sulfur to prevent moisture deterioration.
-
Omicron becomes major epidemic strain in parts of Europe
Time of Update: 2022-02-24
Previously, the number of newly confirmed cases in France exceeded 100,000 for the first time on Christmas Day on the 25th, the highest number of new cases in a single day since the outbreak of the epidemic .
-
Omicron strain may weaken vaccine protection
Time of Update: 2022-02-24
In addition, the Pfizer/Biotech study found that people who had received a third dose of the vaccine had levels of neutralizing antibodies against Omicron that were comparable to those against the other variants .
-
FDA Accelerates Approval of the World's First IgA Nephropathy Drug
Time of Update: 2022-02-24
Article source: Medical Cube InfoOn December 15, Calliditas announced that the FDA has accelerated the approval of budesonide (trade name: Tarpeyo, Nefecon) delayed-release capsules to reduce the risk of rapidly progressive primary IgA nephropathy (usually urinary protein to creatinine ratio ( UPCR) ≥1.
-
Novartis' Cosentyx Approved for Juvenile ERA and Psoriatic Arthritis
Time of Update: 2022-02-24
S. Food and Drug Administration (FDA) has approved Novartis Cosentyx for the treatment of active enthesitis-related arthritis (ERA) in patients four years of age and older, and for the treatment of active psoriatic arthritis in patients two years of age and older.
-
A new breakthrough in the field of recombinant collagen Renewable collagen stick sub-disposable essence leads a new direction of repairing skin care products
Time of Update: 2022-02-24
In the highly market-oriented free competition ecology, Giant Bio has transformed the accumulation of core patented technologies into product power, with the recombination of collagen as the core, in-depth research and development of skin repair and anti-aging products, bringing the current hot functional skin care field.
-
Nature: The first antibody oligonucleotide conjugate enters the clinic
Time of Update: 2022-02-24
Companies currently developing AOC drugs globally include Avidity, Tallac Therapeutics, Dyne Therapeutics, Denali Therapeutics and Gennao Bio .
Dyne's lead drug candidate also targets transferrin receptor 1, but with an antigen-binding fragment rather than a full-length antibody .
-
Super-large study reveals best way to encourage fitness
Time of Update: 2022-02-24
This very large study model allows researchers to compare dozens of different interventions for changing behavior, all of which are designed by an independent research team .
-
Once troubled RNAi technology will eventually make a comeback
Time of Update: 2022-02-24
Dicerna's proprietary RNAi technology platform, called GalXCTM, silences disease genes in the liver .
RNAi technology specifically targets mRNA and modulates protein expression, and has great potential for silencing disease-related genes .
-
mRNA vaccines once again open up new battlefields to challenge latent viruses
Time of Update: 2022-02-23
Today, BioNTech/Pfizer, and Moderna respectively announced new progress in the development of infectious disease vaccines .
de/news-releases/news-release-details/pfizer-and -biontech-sign-new-global-collaboration-agreement[2] MODERNA ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 1 STUDY OF ITS MRNA EPSTEIN-BARR VIRUS (EBV) VACCINE.
-
Study says protein Nsp13 may be a new target for new crown drug development
Time of Update: 2022-02-23
De Pablo said: "We currently only have one treatment for Covid-19, and as the virus mutates, we absolutely need to target different viral building blocks beyond the spike protein .
-
New breakthrough!
Time of Update: 2022-02-23
The related research results will be published in the Journal of Biological Chemistry in December 2021, with the title of "BAd-CRISPR: Inducible gene knockout in interscapular brown adipose tissue of adult mice" .
BAd-CRISPR: Inducible gene knockout in interscapular brown adipose tissue of adult mice.
